The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque ...

The "Plaque Psoriasis Market by Treatment, by Route of Administration, by End-user, and by Region" report has been added to ...

Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

UCB’s 320 mg/2 mL prefilled syringe and autoinjector for single-injection administration option is available now in US: Brussels, Belgium Saturday, January 18, 2025, 16:00 Hrs [ ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality of life for patients with psoriasis.

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...